


Nanon Technologies



Small Currents – Big Potential.

Electrophysiology for transporters
using the “SURFE²R” technology

Dr. Maria Barthmes

Application Scientist & Product Manager SURFE²R Family

Nanon Technologies

nan]i[on

Nanon Technologies introduced




- University spin-off in 2002
- Instrumentation for research, drug screening and safety testing
- One of the leading providers of automated patch clamp systems

- Headquarters located in Munich, Germany
- ~100 employees worldwide
- Offices in USA, Japan, China



Many transporters generate transmembrane currents

- P-Type and F/V-Type ATPases
- Many SLC transporters (coupled transport)



- No labels
- Real time measurement
- High information content
- High experimental freedom


Patch Clamp/Voltage Clamp → low signal amplitude

Oocyte TEVC → low throughput, compound concentrations


SSM-based Electrophysiology → invented for transporters

Solid supported membrane (SSM)-based electrophysiology

high amount of protein = high signal



The sample on the SSM




10 μ l per 96 well plate \sim 0.1 μ g protein/well



Insertion of the Sensor into a recording device


Custom built

SURFE²R N1


3 mm

SURFE²R 96SE


Activation by perfusion of the sensor




Control phase




Substrate is applied → Transport




Wash out of substrate




Experimental scope




Substrates




Inhibition




Environment








Mechanisms



Comparison




OCT2: Development and validation of an assay





OCT2: Development and validation of an assay


3x Topoprint of 120 cells (6 rows x 20 columns) of 20 mM Choline



OCT2: Development and validation of an assay



	SSM	Published
TEA	40 μM	33-270 μM
Choline	1.5 mM	0.46 mM
Metformin	7.3 mM	0.6 -3.3 mM



	SSM	Published
Cimetidine	57 μM	8.6-120 μM
Verapamil	0.6 μM	13.4-85 μM
Quinidine	1.9 μM	8-87 μM

Other validated targets on the SURFE²R

ATPases

NaK-ATPase
HK-ATPase
SERCA
V-ATPase
FoF1-ATPase
Kdp-ATPase
CopA
ATP7A/B
VrPPase

Redox-driven ion pumps

Complex I
respiratory chain complex I/III
respiratory chain complex II/III
cytochrome c-oxidase
respiratory chain complexes I/III/V

Light-driven ion pumps

Bacteriorhodopsin (BR)
Oxyrrhis marina Rhodopsin
Rhodopsin-2 (KR2)
Halorhodopsin (HR)
Acerhodopsin
Channelrhodopsin (ChR)

Pumps

Channels and Pores

Gramicidine
P2X2
nAChR
A/M2
UCP1 (Slc25a7)
TRPC5
TRPA1
CFTR
AQP6

Inorganic ions

NhaA
NhaP
NhaB
NCX1 (Slc8a1)
Clc-7
EcClc
NirC
Amt1-3
AmtB
SulP
NIS (Slc5a5)
NaPi2b (Slc34a2)
MntH2

Amino acids

PEPT1 (Slc15a1)
YdgR
YhiP/DtpB
PutP
GltP
EAAC1 (Slc1a1)
PAT1 (Slc36a1)
ArcD
CAT2B (Slc7a2)
GlyT1/2 (Slc6a9/a5)

Sugars

SGLT1/2 (Slc5a1/a2)
MelB
LacY
FucP
XylE
GlcP

Organic ions

OCT2 (Slc22a2)
CNT1 (Slc28a1)
ANT (Slc25a4)
AAC
GAT1 (Slc6a1)
BetP
CHT (Slc5a7)
NupC
NacT (Slc13a5)

Transporters

Uniporters

Symporters

Exchangers